Bristol-Myers Squibb GmbH & Co. KGaA
ORENCIA® ? (abatacept) Demonstrates Comparable Efficacy to Humira® (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents
Paris (ots/PRNewswire) - ? - ORENCIA demonstrated comparable efficacy to HUMIRA based on a non-inferiority endpoint for ACR20 response at 1 year - Kinetics of response for ACR20, 50 and 70, and inhibition of radiographic progression were generally comparable over 12 months - AMPLE is the first head-to-head study in ...